Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Early Diagnosis Challenging in Pancreatic Cancer

April 8th 2015

Treatment Approaches For Resectable Pancreatic Tumors

April 8th 2015

Treating Borderline Resectable/Locally Advanced Pancreatic Cancer

April 8th 2015

Treating Metastatic Pancreatic Cancer

April 8th 2015

The Role of Clinical Trials

April 8th 2015

Emerging Therapies and Future Treatment Approaches

April 8th 2015

Targeting the Tumor Microenvironment in Treating Pancreatic Cancer

April 8th 2015

Treating Pancreatic Neuroendocrine Tumors

April 8th 2015

Dr. Sotomayor on Personalized Medicine Preventing Cancer

April 7th 2015

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses how personalized medicine may eventually help with preventing cancer.

Rucaparib Receives Breakthrough Designation for BRCA-Positive Advanced Ovarian Cancer

April 6th 2015

The FDA has granted a breakthrough therapy designation to rucaparib as a treatment for women with BRCA-mutated advanced ovarian cancer who have received at least two prior lines of platinum-based chemotherapy.

Crossing Tumor Types: BRCA Experience Points Way to New Diagnostic Paradigm

April 1st 2015

Patients with advanced cancers of the pancreas or prostate, or where progression to this state occurs later in the course of the illness, should have tumor or germline testing performed looking for the presence of a BRCA mutation.

Controversies in Clinical Care: Questioning Research

March 23rd 2015

Maurie Markman, MD, offers examples of clinical trials where the interpretation of study results is worthy of considerable additional discussion or where justification for the actual conduct of the study can be called into question.

Precision Medicine: A Promising Future for Treating Cancer

March 10th 2015

Thomas J. Lynch, MD, director, Yale Cancer Center, Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven, writes about precision medicine in oncology.

Dr. Kim on Evolution of Treatment Outcomes in Melanoma

March 7th 2015

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses how treatment outcomes in melanoma have evolved over the last few years.

NCI Director Harold Varmus Resigns

March 4th 2015

The Nobel Prize winning director of the National Cancer Institute, Harold Varmus, MD, has tendered his resignation to pursue research interests in New York.

GSK, Novartis Product Exchange Completed

March 2nd 2015

GlaxoSmithKline (GSK) and Novartis have announced that a multi-billion-dollar, 3-pronged deal to exchange and share various operations has been completed.

Heterogeneity Complicates Treatment Decisions in Breast Cancer

February 28th 2015

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

Future Treatment Strategies for NSCLC

February 27th 2015

Development of Rociletinib and AZD9291 in NSCLC

February 27th 2015

Third-Generation EGFR Inhibitors in NSCLC

February 27th 2015